A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy was written by Kamegai, Kohei;Iwamoto, Noriko;Togano, Tomiteru;Maeda, Kenji;Takamatsu, Yuki;Miyazato, Yusuke;Ishikane, Masahiro;Mizokami, Masashi;Sugiyama, Masaya;Iida, Shun;Miyamoto, Sho;Suzuki, Tadaki;Ohmagari, Norio. And the article was included in International Journal of Infectious Diseases in 2022.Name: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:
Although mRNA vaccines are substantially effective toward SARS-CoV-2 infection, patients with hematol. malignancies are still prone to the virus. Herein, we report a fatal case of breakthrough SARS-CoV-2 Delta variant infection in a patient with mucosa-associated lymphoid tissue lymphoma with remission by bendamustine-rituximab (BR) therapy completed a year ago. The serol. study revealed impaired responsiveness toward vaccines and prolonged high viral load after infection. BR therapy seemingly induced an immune escape. Prevention and treatment strategies for such vulnerable patients should be clarified immediately. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Name: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Name: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem